Literature DB >> 19672093

Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide.

E Gadermaier1, S Flicker, W Aberer, C Egger, N Reider, M Focke, S Vrtala, M Kundi, R Valenta.   

Abstract

BACKGROUND: Allergen-specific subcutaneous immunotherapy (SCIT) is an antigen-specific therapy of IgE-mediated allergies. In the present study, we analyze the epitope specificities of antibody responses induced by SCIT with allergen extracts from pollen of trees belonging to the order Fagales (birch, alder, hazel) adsorbed onto aluminum hydroxide.
METHODS: The IgE, IgG1-4 and IgA responses to defined recombinant allergens (birch pollen: Bet v 1; alder pollen: Aln g 1; hazel pollen: Cor a 1; apple: Mal d 1) as well as to Bet v 1-derived recombinant fragments and synthetic peptides were analyzed in sera from patients who had undergone SCIT for different periods of time.
RESULTS: Long-term SCIT (>1 year; cumulative dose >1,000,000 SQ units) induced more pronounced IgG1, IgG2 and IgG4 responses to Bet v 1 and Bet v 1-related allergens according to the degree of sequence homology (Bet v 1>Aln g 1>Cor a 1>Mal d 1) than short-term SCIT (<1 year; cumulative dose <1,000,000 SQ units). In contrast to patients treated for <1 year, patients treated for >1 year mounted distinct IgG1, IgG2 and IgG4 responses against sequential Bet v 1 epitopes. No relevant allergen-specific IgA or IgG3 responses were induced by short- or long-term SCIT. Using a competitive ELISA assay, it could be shown that serum IgG from patients undergoing long-term SCIT inhibited IgE reactivity to Bet v 1 better than IgG from patients undergoing short-term SCIT.
CONCLUSION: SCIT with allergen extracts adsorbed onto aluminum hydroxide induces IgG responses against new epitopes that block IgE binding and cross-react with structurally related allergens depending, among other factors, on duration of treatment and cumulative injected dose.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19672093     DOI: 10.1159/000232567

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  12 in total

1.  Identification and validation of shrimp-tropomyosin specific CD4 T cell epitopes.

Authors:  Eugene V Ravkov; Igor Y Pavlov; Thomas B Martins; Gerald J Gleich; Lori A Wagner; Harry R Hill; Julio C Delgado
Journal:  Hum Immunol       Date:  2013-08-28       Impact factor: 2.850

2.  Penaeus monodon tropomyosin induces CD4 T-cell proliferation in shrimp-allergic patients.

Authors:  Shuping Wang; Julio C Delgado; Eugene Ravkov; David D Eckels; Ann Georgelas; Igor Y Pavlov; Matthew Cusick; Kate Sebastian; Gerald J Gleich; Lori A Wagner
Journal:  Hum Immunol       Date:  2011-12-28       Impact factor: 2.850

Review 3.  Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches.

Authors:  R Valenta; R Campana; K Marth; M van Hage
Journal:  J Intern Med       Date:  2012-08       Impact factor: 8.989

Review 4.  From Allergen Molecules to Molecular Immunotherapy of Nut Allergy: A Hard Nut to Crack.

Authors:  Verena Fuhrmann; Huey-Jy Huang; Aysegul Akarsu; Igor Shilovskiy; Olga Elisyutina; Musa Khaitov; Marianne van Hage; Birgit Linhart; Margarete Focke-Tejkl; Rudolf Valenta; Bulent Enis Sekerel
Journal:  Front Immunol       Date:  2021-09-23       Impact factor: 7.561

Review 5.  Antigen-specific immunotherapy of autoimmune and allergic diseases.

Authors:  Catherine A Sabatos-Peyton; Johan Verhagen; David C Wraith
Journal:  Curr Opin Immunol       Date:  2010-09-17       Impact factor: 7.486

Review 6.  Vaccines for allergy.

Authors:  Birgit Linhart; Rudolf Valenta
Journal:  Curr Opin Immunol       Date:  2012-04-20       Impact factor: 7.486

7.  IgE, IgG4 and IgA specific to Bet v 1-related food allergens do not predict oral allergy syndrome.

Authors:  E E Guhsl; G Hofstetter; N Lengger; W Hemmer; C Ebner; R Fröschl; M Bublin; C Lupinek; H Breiteneder; C Radauer
Journal:  Allergy       Date:  2014-11-30       Impact factor: 13.146

8.  Determination of allergen specificity by heavy chains in grass pollen allergen-specific IgE antibodies.

Authors:  Elisabeth Gadermaier; Sabine Flicker; Christian Lupinek; Peter Steinberger; Rudolf Valenta
Journal:  J Allergy Clin Immunol       Date:  2012-11-30       Impact factor: 10.793

9.  Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.

Authors:  Petra Zieglmayer; Margarete Focke-Tejkl; René Schmutz; Patrick Lemell; René Zieglmayer; Milena Weber; Renata Kiss; Katharina Blatt; Peter Valent; Frank Stolz; Hans Huber; Angela Neubauer; Anette Knoll; Friedrich Horak; Rainer Henning; Rudolf Valenta
Journal:  EBioMedicine       Date:  2016-08-20       Impact factor: 8.143

10.  Epitope specificity determines cross-protection of a SIT-induced IgG4 antibody.

Authors:  E Gadermaier; L K James; M H Shamji; K Blatt; K Fauland; P Zieglmayer; T Garmatiuk; M Focke-Tejkl; M Villalba; R Beavil; W Keller; P Valent; S R Durham; H J Gould; S Flicker; R Valenta
Journal:  Allergy       Date:  2015-09-30       Impact factor: 13.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.